Clinical trial NCT05050669: Natural History Study of ENPP1 Deficiency and the Early-onset Form of ABCC6 Deficiency
Official title: A Prospective Observational Study to Evaluate Disease Presentation and Progression in Subjects With ENPP1 Deficiency and the Early-Onset Form of ABCC6 Deficiency
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency
ATP-Binding Cassette Subfamily C Member 6 Deficiency
Generalized Arterial Calcification of Infancy
Autosomal Recessive Hypophosphatemic Rickets
Keywords: ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency
ENPP1
ATP-binding cassette subfamily C member 6 deficiency
ABCC6
Generalized Arterial Calcification of Infancy
GACI
Autosomal Recessive Hypophosphatemic Rickets Type 2
ARHR2
hypopyrophosphatemia
Lead sponsor: Inozyme Pharma
Sponsor class: INDUSTRY
First posted: 2021-09-20
Enrollment: 12
Sex: ALL
Minimum age (years): 2
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: This study will enroll all eligible subjects aged 2 to \<18 years with ENPP1 Deficiency and the early-onset form of ABCC6 Deficiency who consent to participate, with the goal of recruiting up to 20 subjects.

Brief summary: The purpose of this prospective study is to characterize the natural history of ENPP1 Deficiency and the early-onset form of ABCC6 Deficiency longitudinally. The study will prospectively gather information about the biochemical, physiological, anatomic, radiographic, and functional manifestations (including patient reported outcomes) of each disease.

Detailed description: Study INZ701-003 is a multicenter, prospective, longitudinal, observational study to evaluate disease presentation, progression, and burden of illness in pediatric subjects aged 2 to \<18 years with ENPP1 Deficiency and the early-onset form of ABCC6 Deficiency. Subjects will receive care available at the clinical site along with additional assessments administered by the study team.

To participate in this study, subjects will give informed assent and parents/guardians will provide informed consent.

Subject participation will consist of a Screening Period and an Observation Period.

Assessments will be performed at each visit as indicated in the Schedule of Events.

During the Screening Period, assessments will be performed to determine eligibility.

Screening and Baseline assessments may be conducted on the same day if the Investigator determines that the patient can successfully complete all study procedures in one day due to their age. If not, sites may schedule additional visits, as needed. A subject will be enrolled into the study if they meet all eligibility criteria.

During the Observation Period, subjects will be assessed for changes in their disease in the following areas: measurements of physiological function (including laboratory testing and anatomical and radiographical assessment of calcification and bone mineralization); performance outcomes; patient, caregiver, and physician reported outcomes; and healthcare utilization.

Eligibility criteria: Inclusion Criteria:

Individuals eligible to participate must meet all of the following inclusion criteria:

1. Must provide written consent of the legally authorized representative/caregiver and assent for subjects after the nature of the study has been explained and prior to any research-related procedures, following the policies of the clinical site
2. Genetic confirmation of ENPP1 Deficiency or ABCC6 Deficiency
3. Male or female, aged 2 to \<18 years
4. In the opinion of the Investigator, must be willing and able to complete all aspects of the study
5. Agree to provide access to relevant medical records

Exclusion Criteria:

Individuals who meet the following exclusion criterion will not be eligible to participate:

1. In the opinion of the Investigator and/or Sponsor, presence of any clinically significant disease (outside of those considered associated with the diagnosis of ENPP1 Deficiency or the early-onset form of ABCC6 Deficiency) that precludes study participation or may confound interpretation of study results, such as an unrelated bone, mineral, or muscle disease or genetic connective tissue disease

Primary outcomes:
measure: Measurement of Plasma Inorganic Pyrophosphate (PPi) in Plasma
timeFrame: Up to 12 months
measure: Determination of Arterial Calcification
timeFrame: Up to 12 months
measure: Determination of Organ Calcification
timeFrame: Up to 12 months
measure: Determination of skeletal radiographs
timeFrame: Up to 12 months
measure: Determination of range of motion
timeFrame: Up to 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Boston
country: United States
facility: Boston Children's Hospital
state: Massachusetts
city: Philadelphia
country: United States
facility: CHOP - Robers Center for Pediatric Research
state: Pennsylvania
city: Fort Worth
country: United States
facility: Cook Children's Hospital
state: Texas
city: Montréal
country: Canada
facility: CHU Sainte-Justine
state: Quebec
city: Manchester
country: United Kingdom
facility: Royal Manchester University Hospital
Study officials:
affiliation: Inozyme Pharma, Inc.
name: Kurt Gunter, MD
role: STUDY_DIRECTOR
References: